# US 2013/0336996 A1 · Novel compositions of tlr7 and/or tlr8 agonists conjugated to lipids

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2013/0336996 A1
- Document ID: US20130336996A1
- Status: Published application
- Kind: A1
- Application number: 13/832,477
- Filed: 2013-03-15
- Published: 2013-12-19
- Earliest claimed: 2012-06-15
- Assignees: Cayla
- Applicants: Cayla
- Inventors: Fabienne VERNEJOUL; Arnaud DEBIN; Daniel DROCOURT; Eric PEROUZEL; Gerard TIRABY; Thierry LIOUX
- Web page: https://patentgrep.com/patent/US20130336996A1

## CPC

- C07F 9/6512: having the nitrogen atoms in positions 1 and 3
- A61K 47/543: {Lipids, e.g. triglycerides; Polyamines, e.g. spermine or spermidine}
- A61K 47/544: {Phospholipids}
- A61K 47/554: {the modifying agent being a steroid plant sterol, glycyrrhetic acid, enoxolone or bile acid}
- A61P 31/00: Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P 35/00: Antineoplastic agents
- A61P 37/00: Drugs for immunological or allergic disorders
- C07D 471/04: Ortho-condensed systems
- C07F 9/65068: {condensed with carbocyclic rings or carbocyclic ring systems}
- C07J 43/003: {not condensed}
- C07F: ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM (metal-containing porphyrins C07D487/22)
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- C07D: HETEROCYCLIC COMPOUNDS (macromolecular compounds C08)
- C07J: STEROIDS (seco-steroids C07C)

## Abstract

A conjugated compound of formula Q-Z—R4 wherein Q is a TLR7 and/or TLR8 agonist and Z—R4 is a lipid covalently linked to an amino acid or peptide coupled to a polyamine group, and a process for the manufacture of the conjugated compound, as well as a complex formed between the conjugated compound and a polyanionic molecule and a pharmaceutical composition containing the conjugated compound or complex. Also described is the use of the conjugated compound or complex in the treatment of infection, cancer or immune disorders or for use in vaccines.

## Claims

### Claim 1

A conjugated compound of formula (I):
Q-Z—R4 (I)
wherein Q is an imidazoquinoline, a purine or a 3-deazapurine derivative agonist of TLR7 and/or TLR8,
said conjugated compound being chosen among compounds of formula (I′):
a tautomer thereof or a pharmaceutically acceptable salt, solvate or polymorph of said compound or tautomer, wherein:
R1 is —H, —OH, —SH, —NH2, —CF3, halogen, or a group chosen from C1-C6alkyl, C1-C6alkylamino, C1-C6alkoxy, C3-C6cycloalkyl-C1-C6alkyl, C3-C6cycloalkyl-C1-C6alkylamino, C3-C6cycloalkyl, C1-C6alkoxyC1-C6alkylamino, or C1-C6alkoxyC1-C6alkoxy, (C1-C6alkyl)-E-(C1-C6alkylene)- wherein E is —O—, —S—, —N(R12)—, —C(O)— or —S(O)2— and R12 is —H, carboxyl, —NH2, C1-C6alkyl, C1-C6alkoxy, C1-C6alkanoyl, C6-C20aryl, C6-C20 heteroaryl, or C1-C6alkoxycarbonyl, said group being optionally terminally substituted with a hydroxyl, amino, thiol, hydrazino, hydrazido, azido, acetylenyl, carboxyl, or maleimido group;
A is a nitrogen atom, R3 is absent and R2 is H, OH, SH, NH2, CF3, halogen, C1-C10alkyl, C1-C10alkylamino, C1-C10dialkylamino, C1-C10alkoxy, C1-C10alkoxy-C1-C10 alkylamino, C1-C10alkoxy-C1-C10alkoxy, C1-C10alkoxy-C5-C7heterocycle, C1-C10alkyamino-C5-C7heterocycle, —NH—SO2—C1-C6alkyl, —C(O)—C1-C6alkyl, —O—C(O)—C1-C6alkyl, —C(O)—C1-C10alkylamino, —C(O)—C1-C10dialkylamino, C5-C10aryl, C5-C9heterocyclyl, C3-C9 carbocyclyl, C1-C10alkylamino-C2-C7heterocycle, (C1-C6alkoxy)-E-(C1-C6alkylene) and preferably R1 is —H, —OH, —SH, —NH2, C1-C6alkyl, such as methyl, ethyl, propyl or butyl, C1-C6alkylamino such as methylamino, ethylamino, propylamino or butylamino, C1-C6alkoxy such as methoxy, ethoxy, propoxy or butoxy, (C1-C6alkyl)-E-(C1-C6alkylene), wherein E is —O— or —NH—, such as —CH2—NH—C2H5, —CH2—O—C2H5, —(CH2)2—NH—CH3, or —(CH2)2—O—CH3, more preferably R1 is —OH, or
A is a carbon atom and R2 and R3 form together a fused phenyl optionally substituted with one or more groups independently selected from F, Cl, Br, I, —CH3, —CH2CH3, CH2CH(CH3)2, —CH2OH, —CH2CH2OH, —C(CH3)2OH, —CH(OH)CH(CH3)2, —C(CH3)2CH2OH, —CH2CH2SO2CH3, —CN, —CF3, —CHF2, —CO2H, —COCH3, —CO2CH3, —C(CH3)2CO2CH3, —CO2C(CH3)3, —COCH(OH)CH3, —COCH(CH3)2, —CONH2, —CONHCH3, —CON(CH3)2, —C(CH3)2CONH2, —NO2, —NH2, —NHCH3, —N(CH3)2, —NHCOCH3, —N(CH3)COCH3, —NHS(O)2CH3, —N(CH3)C(CH3)2CONH2, —N(CH3)CH2CH2S(O)2CH3, —OH, —OCH3, —S(O)2N(CH3)2, —SCH3, —CH2OCH3, —S(O)2CH3, cyclopropyl, oxetanyl, and morpholino, and preferably R1 is —H, —OH, —SH, —NH2, C1-C6alkyl, such as methyl, ethyl, propyl or butyl, C1-C6alkylamino such as methylamino, ethylamino, propylamino or butylamino, C1-C6alkoxy such as methoxy, ethoxy, propoxy or butoxy, (C1-C6alkyl)-E-(C1-C6alkylene), wherein E is —O— or —NH—, such as —CH2—NH—C2H5, —CH2—O—C2H5, —(CH2)2—NH—CH3, or —(CH2)2—O—CH3, or
A is a carbon atom and R2 and R3 independently from each other are H, OH, SH, NH2, CF3, halogen, C1-C10alkyl, C1-C10alkylamino, C1-C10dialkylamino, C1-C10alkoxy, C1-C10alkoxy-C1-C10 alkylamino, C1-C10alkoxy-C1-C10alkoxy, C1-C10alkoxy-C5-C7heterocycle, C1-C10alkyamino-C5-C7heterocycle, —NH—SO2—C1-C6alkyl, —C(O)—C1-C6alkyl, —O—C(O)—C1-C6alkyl, —C(O)—C1-C10alkylamino, —C(O)—C1-C10dialkylamino, C5-C10aryl, C5-C9heterocyclyl, C3-C9 carbocyclyl, C1-C10alkyl amino-C2-C7heterocycle, (C1-C6alkoxy)-E-(C1-C6alkylene) and preferably R1 is —H, —OH, —SH, —NH2, C1-C6alkyl, such as methyl, ethyl, propyl or butyl, C1-C6alkylamino such as methylamino, ethylamino, propylamino or butylamino, C1-C6alkoxy such as methoxy, ethoxy, propoxy or butoxy, (C1-C6alkyl)-E-(C1-C6alkylene), wherein E is —O— or —NH—, such as —CH2—NH—C2H5, —CH2—O—C2H5, —(CH2)2—NH—CH3, or —(CH2)2—O—CH3, more preferably R1 is —OH; and
s is an integer from 1 to 4;
X is an unbranched —(C1-C6 alkylene)-, —(C6-C20arylene)-, —(C4-C20heteroarylene)-, —(C1-C6 alkylene)-E-(C1-C6 alkylene)-, —(C1-C6 alkylene)-(C3-C7-carbocyclylene)-, —(C1-C6 alkylene)-(C3-C7-heterocyclylene)-, —(C1-C6 alkylene)-(C6-C20 arylene)-, —(C1-C6 alkylene)-(C4-C20 heteroarylene)-, —(C1-C6 alkylene)-E-(C1-C7 carbocyclylene)-, —(C1-C6 alkylene)-E-(C3-C7-heterocyclylene)-, —(C1-C6 alkylene)-E-(C6-C20 arylene)-, —(C1-C6 alkylene)-E-(C4-C20 heteroarylene)-, where alkylene, carbocyclylene, heterocyclylene, arylene, and heteroarylene are optionally substituted with one or more groups independently selected from F, Cl, Br, I, —CH3, —CH2CH3, CH2CH(CH3)2, —CH2OH, —CH2CH2OH, —C(CH3)2OH, —CH(OH)CH(CH3)2, —C(CH3)2CH2OH, —CH2CH2SO2CH3, —CN, —CF3, —CHF2, —CO2H, —COCH3, —CO2CH3, —C(CH3)2CO2CH3, —CO2C(CH3)3, —COCH(OH)CH3, —COCH(CH3)2, —CONH2, —CONHCH3, —CON(CH3)2, —C(CH3)2CONH2, —NO2, —NH2, —NHCH3, —N(CH3)2, —NHCOCH3, —N(CH3)COCH3, —NHS(O)2CH3, —N(CH3)C(CH3)2CONH2, —N(CH3)CH2CH2S(O)2CH3, —OH, —OCH3, —S(O)2N(CH3)2, —SCH3, —CH2OCH3, —S(O)2CH3, cyclopropyl, oxetanyl, and morpholino, and E is as defined above;
Y is a single bond, —O—, —S—, —N(R12)—, —C(O)—, or —S(O)2— and R12 is as defined above; and
Z—R4 is selected from the group consisting of:
wherein:
R6 is the specific side chain of an amino acid;
l is 0 or 1;
p is integer from 0 to 6;
m, n, o, and q, identical or different, are integers from 1 to 4; and
R4 is a lipid of formula VII or VIII:
wherein:
R7 and R8 independently of each other are a linear or branched hydrocarbon chain comprising from 10 to 24 carbon atoms, and which optionally contains from 2 to 4 double or triple bonds,
G1 is a single bond, —NH— or —O—,
G2 is a single bond or (—CH2—)r, and
r is an integer from 1 to 6.

### Claim 2 (depends on 1)

The conjugated compound according to claim 1, wherein —Z— is selected from the group consisting of:

### Claim 3 (depends on 1)

The conjugated compound according to claim 1, wherein R4 is of formula (VII):
wherein:
r is an integer from 1 to 4, preferably 3,
G1 is a single bond,
R7 and R8, identical or different, preferably identical, are selected from the group consisting of tetradecyl, hexadecyl, octadecyl, oleyl, phytanyl, C18:2 alkenyl, C18:3 alkenyl or C18:1 alkenyl.

### Claim 4 (depends on 1)

The conjugated compound according to claim 1, wherein R4 is of formula (VIII):
wherein G2 is a single bond or (—CH2—)r, wherein r is an integer from 1 to 6.

### Claim 5 (depends on 1)

The conjugated compound according to claim 1, wherein Y is a single bond or —CO—, —N(R5)—, —O—, —S— or —S(O)2—, wherein R5 is —H, carboxyl, —NH2 or a radical chosen from C1-C6alkyl, C1-C6alkoxy, C1-C6alkanoyl, C6-C20aryl, C6-C20 heteroaryl, or C1-C6alkoxycarbonyl.

### Claim 6 (depends on 1)

The conjugated compound according to claim 1, wherein X is a —(C6-C20arylene), preferably a phenylene, a —(C1-C6 alkylene)-, preferably an ethylene, a —(C6-C20heteroarylene)-, preferably a pyridinylene, a —(C1-C6 alkylene)-W—(C1-C6 alkylene)-, preferably an ethylene-W-ethylene wherein W is —O— or —NH—.

### Claim 7 (depends on 1)

The conjugated compound according to claim 1, wherein s is 1.

### Claim 8 (depends on 1)

The conjugated compound according to claim 1, wherein R1 is —H, —OH, C1-C6alkyl, or (C1-C6alkyl)-W—(C1-C6alkylene), wherein W is —O— or —NH—.

### Claim 9 (depends on 1)

The conjugated compound according to claim 1, wherein A is a nitrogen atom.

### Claim 10 (depends on 1)

The conjugated compound according to claim 1, wherein:
A is a nitrogen atom, R2 is a C1-C6alkylamino or C1-C10alkoxy-C1-C10alkoxy, and R3 is absent or
R2 and R3 form a fused C6-C20 aryl, preferably a phenyl.

### Claim 11 (depends on 1)

The conjugated compound according to claim 1, wherein said conjugated compound is selected from the group consisting of:
bis(3,7,11,15-tetramethylhexadecyl) 1-(4-((6-amino-2-(butylamino)-8-hydroxy-9H-purin-9-yl)methyl)phenyl)-1-oxo-2,6,11,15-tetraazaoctadecan-18-ylphosphonate,
bis(3,7,11,15-tetramethylhexadecyl) 1-(4-((6-amino-2-(butylamino)-8-hydroxy-9H-purin-9-yl)methyl)phenyl)-1,4-dioxo-2,5,9,14,18-pentaazahenicosan-21-ylphosphonate,
di(Z)-octadec-9-enyl 1-(4-((6-amino-2-(butylamino)-8-hydroxy-9H-purin-9-yl)methyl)phenyl)-1-oxo-2,6,11,15-tetraazaoctadecan-18-ylphosphonate,
di(Z)-octadec-9-enyl 1-(4-((6-amino-2-(butylamino)-8-hydroxy-9H-purin-9-yl)methyl)phenyl)-1,4-dioxo-2,5,9,14,18-pentaazahenicosan-21-ylphosphonate,
dihexadecyl 1-(4-((6-amino-2-(butylamino)-8-hydroxy-9H-purin-9-yl)methyl)phenyl)-1-oxo-2,6,11,15-tetraazaoctadecan-18-ylphosphonate,
dihexadecyl 1-(4-((6-amino-2-(butylamino)-8-hydroxy-9H-purin-9-yl)methyl)phenyl)-1,4-dioxo-2,5,9,14,18-pentaazahenicosan-21-ylphosphonate,
(S)-dihexadecyl 19-amino-5-(4-(2-(4-((6-amino-2-(butylamino)-8-hydroxy-9H-purin-9-yl)methyl)benzamido)acetamido)butyl)-6-oxo-4,7,11,16-tetraazanonadecylphosphonate,
(S)-bis(3,7,11,15-tetramethylhexadecyl)-19-amino-5-(4-(2-(4-((6-amino-2-(butylamino)-8-hydroxy-9H-purin-9-yl)methyl)benzamido)acetamido)butyl)-6-oxo-4,7,11,16-tetraazanonadecylphosphonate,
(S)-Dihexadecyl-1-amino-15-(2-(4-((6-amino-2-(butylamino)-8-hydroxy-9H-purin-9-yl)methyl)benzamido)acetamido)-14-oxo-4,9,13,20-tetraazatricosan-23-ylphosphonate,
(S)-bis(3,7,11,15-tetramethylhexadecyl)-1-amino-15-(2-(4-((6-amino-2-(butylamino)-8-hydroxy-9H-purin-9-yl)methyl)benzamido)acetamido)-14-oxo-4,9,13,20-tetraazatricosan-23-ylphosphonate,
(S)-Dihexadecyl-1-amino-15-(4-((6-amino-2-(butylamino)-8-hydroxy-9H-purin-9-yl)methyl)benzamido)-14-oxo-4,9,13,20-tetraazatricosan-23-ylphosphonate,
(S)-bis(3,7,11,15-tetramethylhexadecyl)-1-amino-15-(4-((6-amino-2-(butylamino)-8-hydroxy-9H-purin-9-yl)methyl)benzamido)-14-oxo-4,9,13,20-tetraazatricosan-23-ylphosphonate,
(S)-dihexadecyl-21-amino-5-(4-((6-amino-2-(butylamino)-8-hydroxy-9H-purin-9-yl)methyl)phenylcarbamoyl)-8-oxo-4,9,13,18-tetraazahenicosylphosphonate,
bis(3,7,11,15-tetramethylhexadecyl)-(S)-21-amino-5-(4-((6-amino-2-(butylamino)-8-hydroxy-9H-purin-9-yl)methyl)phenylcarbamoyl)-8-oxo-4,9,13,18-tetraazahenicosylphosphonate,
bis(3,7,11,15-tetramethylhexadecyl)-1-(4-((4-amino-2-butyl-1H-imidazo[4,5-c]quinolin-1-yl)methyl)phenyl)-1-oxo-2,6,11,15-tetraazaoctadecan-18-ylphosphonate
(S)-dihexadecyl-21-amino-5-(3-(4-amino-2-(ethoxymethyl)-1H-imidazo[4,5-c]quinolin-1-yl)propylcarbamoyl)-8-oxo-4,9,13,18-tetraazahenicosylphosphonate,
bis(3,7,11,15-tetramethylhexadecyl)-(S)-21-amino-5-(3-(4-amino-2-(ethoxymethyl)-1H-imidazo[4,5-c]quinolin-1-yl)propylcarbamoyl)-8-oxo-4,9,13,18-tetraazahenicosylphosphonate,
bis(3,7,11,15-tetramethylhexadecyl)-(S)-21-amino-5-(3-(4-amino-2-((ethylamino)methyl)-1H-imidazo[4,5-c]quinolin-1-yl)propylcarbamoyl)-8-oxo-4,9,13,18-tetraazahenicosylphosphonate, and
(3S,8S,9S,10R,13R,14S,17R)-10,13-dimethyl-17-((R)-6-methylheptan-2-yl)-2,3,4,7,8,9,10,11,12,13,14,15,16,17-tetradecahydro-1H-cyclopenta[a]phenanthren-3-yl 3-(4-(3-(4-((6-amino-2-(butylamino)-8-hydroxy-9H-purin-9yl)methyl)benzamido)propylamino)butylamino) propylcarbamate,
a tautomer thereof or a pharmaceutically acceptable salt, solvate or polymorph of said compound or tautomer.

### Claim 12 (depends on 1)

A process for the manufacture of the compounds of formula (I′) according to claim 1, which process comprises reacting a compound of formula (XII):
wherein R1, R2, R3, A, s, X and Y are as previously defined,
with a compound of formula (XIII):
H—Z—R4 (XIII)
wherein Z and R4 are as previously defined,
or reacting a compound of formula (XIV):
wherein R1, R2, R3, A, s, X, Y and Z are as previously defined, and P2 is a protecting group,
with a compound of formula (XV):
L-R4 (XV)
wherein R4 is as previously defined, and L is a leaving group.

### Claim 13 (depends on 1)

A complex formed between a polyanionic molecule and the conjugated compound according to claim 1 in a medium having a pH comprised between 4 and 8.

### Claim 14 (depends on 1)

A pharmaceutical composition comprising the conjugated compound according to claim 1 and a pharmaceutically acceptable excipient or carrier.

### Claim 15 (depends on 13)

A pharmaceutical composition comprising the complex according to claim 13 and a pharmaceutically acceptable excipient or carrier.

### Claim 16 (depends on 1)

A vaccine comprising the conjugated compound according to claim 1.

### Claim 17 (depends on 13)

A vaccine comprising the complex according to claim 13.

### Claim 18 (depends on 1)

A method for treating pathology selected from the group consisting of an infection, a cancer and an immune disorder in a subject in need thereof comprising administering to said subject a therapeutically effective amount of the conjugated compound according to claim 1.

### Claim 19 (depends on 13)

A method for treating an infection, a cancer and an immune disorder in a subject in need thereof comprising administering to said subject a therapeutically effective amount of the complex according to claim 13.

### Claim 20 (depends on 1)

A method for inducing an immune response via TLR7 and/or TLR8 pathway(s) in a patient, comprising administering to said patient a therapeutically effective amount of the conjugated compound according to claim 1.

### Claim 21 (depends on 13)

A method for inducing an immune response via TLR7 and/or TLR8 pathway(s) and/or cytosolic nucleic acids sensors pathway(s) in a patient, comprising administering to said patient a therapeutically effective amount of the complex according to claim 13, in particular in the form of complex with a polyanionic molecule.
